In 1942, the U.S. Patent Office rejected a claim on a new variety of cultivated hemp on the grounds that living plants were products of nature and therefore unpatentable. Eighty years later, that legal principle has been almost entirely dismantled — and the cannabis industry is now living with the consequences.
More than 1,600 cannabis-related patents have been granted or filed in the United States alone. Thousands more are pending internationally. The filings cover everything from specific THC-to-CBD ratios to the precise geometry of vaporizer cartridges to synthetic routes for producing cannabinoids in bacterial cultures. Some are narrow and defensible. Others are breathtakingly broad — sweeping claims on entire classes of cannabinoid compounds that human beings have grown, consumed, and traded for millennia.
The patent wars have arrived in cannabis, and for the craft growers, small dispensaries, and independent cultivators who built this industry from the underground up, the stakes could not be higher.
How We Got Here: A Brief History of Plant Patents
The legal right to patent a living organism has been contested for most of the 20th century. The landmark turning point came in 1980, when the U.S. Supreme Court ruled in Diamond v. Chakrabarty that a genetically modified bacterium was patentable. The decision cracked open the door for biotech patents on living systems.
In 1985, the U.S. Patent and Trademark Office extended that logic to plants, allowing utility patents on new crop varieties. By 1988, the first patent on an animal — the Harvard OncoMouse — was granted. Cannabis, still federally classified as a Schedule I substance, was largely excluded from this patent gold rush simply because federal agencies would not process applications for illegal substances.
That firewall has been eroding steadily. The DEA’s loosening of research restrictions, the rescheduling debate, and the explosion of hemp after the 2018 Farm Bill all opened the floodgates. USPTO examiners began granting cannabis patents at scale. The number of applications has roughly doubled every three years since 2015, and there is no sign of the curve flattening.
The Major Players Staking Their Claims
GW Pharmaceuticals / Jazz Pharma is the most visible actor in cannabis IP. The British company spent decades developing Sativex and Epidiolex, the first FDA-approved cannabidiol drug, and it holds a dense portfolio of patents covering CBD formulations, extraction methods, and specific therapeutic applications. When Jazz Pharmaceuticals acquired GW in 2021 for $7.2 billion, it also acquired that IP fortress. Critics note that GW’s patents on CBD-based epilepsy treatments are so broadly written that they could theoretically cover a wide range of CBD products sold in dispensaries today — a legal exposure that almost no one in the retail cannabis market is equipped to fight.
Canopy Growth, the Canadian cannabis giant, has aggressively pursued patents across cultivation techniques, formulation chemistry, and cannabis-infused beverages. The company has filed hundreds of applications globally and has been accused by smaller competitors of using its legal department as a competitive weapon — filing patents not because it plans to use the underlying technology, but to create legal risk for rivals who might.
United Cannabis Corp (UCANN) filed one of the most controversial patents in the industry’s history: a broad claim covering liquid cannabis extracts with high concentrations of cannabinoids. The patent, granted in 2018, was widely interpreted as an attempt to own the concept of concentrated cannabis oil. UCANN subsequently sued multiple companies for infringement. The litigation was eventually dismissed on procedural grounds, but the episode served as a warning shot.
Shell companies and patent trolls represent perhaps the most troubling development. A growing number of cannabis-related patents are filed by entities with no public presence, no product, and no history of operating in the industry. These non-practicing entities — known colloquially as patent trolls — acquire IP portfolios with the sole intent of licensing them aggressively or extracting settlements from businesses that lack the resources to litigate.
A Taxonomy of Cannabis Patents
Understanding what is actually being claimed requires parsing the three main categories of cannabis intellectual property.
Plant patents protect new, distinct, and asexually reproduced plant varieties. In cannabis, this means specific cultivars with novel genetic profiles. A breeder who develops a strain with, say, an unusually high concentration of a rare cannabinoid like THCV and a novel terpene expression can theoretically patent that cultivar. Plant patents are generally narrower and more defensible because they require genuine novelty. The problem arises when companies file plant patents on strains they did not actually develop — strains that have been circulating in the underground market for decades.
Utility patents are far more powerful and far more dangerous. These patents cover processes, methods, and compositions — meaning a company can claim the method of extracting a particular cannabinoid, the process of encapsulating it in a nanoparticle, or the formulation of a specific ratio of compounds. Utility patents are what GW and UCANN have wielded most effectively. Because utility patents can cover broad categories of activity rather than a single specific product, a well-drafted utility patent can functionally monopolize an entire segment of the market.
Formulation patents are a subset of utility patents that cover the specific combination of ingredients in a cannabis product — a particular tincture recipe, a specific edible formulation, a transdermal patch design. These are increasingly common as companies seek to differentiate products in a crowded market, and they are increasingly being used to block competitors from developing similar products.
The Ethical Fault Line
The central ethical question in cannabis patenting is simple to state and nearly impossible to resolve within the existing legal framework: can you patent something that nature made, and that humans have cultivated and improved over thousands of years?
Cannabis has been selectively bred by human communities across Central Asia, South Asia, the Middle East, and Africa for at least 10,000 years. The genetic diversity of the plant reflects millennia of human cultivation — much of it by people who will never see a dime from the patent system. When a biotech company files a utility patent on a cannabinoid formulation that tribal healers in Nepal have used for centuries, the moral calculus is difficult to defend.
Patent law, however, does not recognize traditional knowledge as prior art in most jurisdictions. To invalidate a patent on prior art grounds, you need documented, publicly accessible prior art — published research, registered products, or filed patents. Oral traditions and undocumented cultivation practices typically do not qualify. This legal gap is precisely what large corporate actors exploit.
The cannabis community has also raised a more pragmatic objection: the people who built this industry — the underground growers who maintained rare genetics through decades of prohibition, the patient advocates who funded early clinical observations, the Black and Latino communities who bore the brunt of the drug war — are largely absent from the patent landscape. The IP bonanza is accruing almost entirely to well-capitalized corporations.
Inside the Patent Landscape
Explore our Patent Landscape Explorer below to see how cannabis IP is distributed across categories and companies — from cultivation methods to cannabinoid formulations to delivery systems — and which players are filing the most aggressive claims.
The distribution is not random. Patents cluster heavily in a handful of categories: extraction and purification methods, cannabinoid formulations, and delivery systems (especially inhalation devices). Cultivation method patents are less common but growing fast, driven by indoor growing technology companies seeking to protect proprietary lighting, nutrient, and climate control systems. The geographic concentration is equally striking — California, Colorado, and Washington account for the plurality of domestic filers, but a disproportionate share of the broad, aggressive utility patents come from entities incorporated in Delaware with no operational presence in any cannabis state.
The Craft Grower’s Dilemma
For independent cultivators and small cannabis businesses, the patent landscape presents a threat that is difficult to quantify and almost impossible to manage. A small dispensary operator cannot afford a freedom-to-operate analysis — the legal review that determines whether a product or process infringes existing patents — for every item on the shelf. A craft grower developing a new cultivar has no way to know whether some element of their breeding program is already claimed.
The asymmetry is stark. Filing a patent costs thousands of dollars in attorney fees and USPTO filing fees. Defending against a patent infringement lawsuit costs millions. Large companies know this math. When a well-funded cannabis company sends a cease-and-desist letter to a small grower or processor, the rational response for the small operator is often to settle — not because they have infringed anything, but because litigation is financially ruinous regardless of merit.
Several small cannabis companies have reported receiving demand letters from entities they had never heard of, claiming royalties on extraction processes or formulation methods. Most of these cases settle quietly. The ones that proceed to litigation often end in dismissal, but only after the small company has spent six figures in legal fees.
Cannabis advocacy organizations have begun pushing for a prior art database — a publicly accessible, searchable repository of cannabis cultivation techniques, extraction methods, and traditional uses that could be cited during patent examination to narrow or reject overbroad claims. The effort is nascent and underfunded, but it represents the most practical near-term defense available to the craft sector.
Defensive Patenting: The Lesser Evil?
Some cannabis companies have adopted a defensive patenting strategy — filing patents not to assert them against competitors, but to prevent larger players from doing so first. The logic is similar to nuclear deterrence: if we hold the patent, you cannot use it to shut us down.
Harborside, one of the oldest and most respected dispensaries in California, has explored this approach. So have several cannabis research consortiums that have filed patents on novel extraction techniques with the stated intent of licensing them on non-exclusive, royalty-free terms to the broader industry. The Open Cannabis Project attempted to publish prior art documentation specifically to block patent grants on existing varieties and methods.
Defensive patenting is imperfect — it still concentrates IP in the hands of those who can afford attorneys — but it has emerged as one of the few viable tools available to industry participants who lack the resources to litigate their way out of a patent assault.
The International Dimension
The U.S. patent landscape does not exist in isolation. The European Patent Office has granted cannabis-related patents at a slower pace, partly because European patent law historically required a higher standard of inventiveness and had stronger traditional knowledge protections. Canada, which legalized cannabis federally in 2018, has seen a surge in cannabis patent filings since legalization — many of them from the same large companies dominating the U.S. landscape.
Israel presents a fascinating counterexample. The country has been a global leader in cannabis research since the 1960s, when Raphael Mechoulam first isolated THC. Israeli patent law includes provisions that have historically made it difficult to patent naturally occurring plant compounds without demonstrating significant technical innovation. The result is a more open research environment that has produced more scientific publication and less IP hoarding than the U.S. market — though that dynamic is beginning to change as commercial interests intensify.
In markets where cannabis is still illegal or only recently legalized, patent filing is accelerating ahead of legalization, as companies seek to establish IP positions before markets open. Germany’s recent legalization has triggered a wave of European filings that observers expect to generate significant litigation as the market matures.
What Comes Next
The cannabis patent wars are early innings. As federal legalization in the United States becomes increasingly likely, the stakes will rise dramatically. A federally legal cannabis market worth hundreds of billions of dollars will attract the full resources of pharmaceutical, agricultural, and consumer goods companies — all of whom will arrive with IP teams and litigation war chests that dwarf anything the current cannabis industry has seen.
The craft sector’s best hope may lie in the courts. Several broad cannabis utility patents have already been challenged through inter partes review — a USPTO process that allows third parties to challenge the validity of granted patents. Early results have been mixed, but the process has successfully narrowed or invalidated several overbroad claims.
Legislative intervention is also possible. Multiple cannabis reform bills introduced in Congress have included provisions addressing the patent asymmetry — requiring enhanced prior art review for cannabis patents, mandating access to government-funded cannabis research for small businesses, or establishing royalty-free licensing requirements for patents that cover traditional cultivation practices.
None of these remedies are guaranteed. The pharmaceutical and biotech industries spend more on lobbying than any other sector in the U.S. economy, and they will not cede IP protections without a fight.
The plant has survived thousands of years of human history. Whether the craft growers and small operators who carried it through prohibition can survive the patent wars is a different question entirely — and the answer will be written in the next decade.